Ancestry-Driven Recalibration of Tumor Mutational Burden and Disparate Clinical Outcomes in Response to Immune Checkpoint Inhibitors

Ancestry-Driven Recalibration of Tumor Mutational Burden and Disparate Clinical Outcomes in Response to Immune Checkpoint Inhibitors

header-info

Using two clinical cohorts, the study authors investigated the interplay between genetic ancestry, TMB, and tumor-only versus tumor-normal paired sequencing in solid tumors.